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Which NeWly-DiagNoseD DiaBetics shoulD Receive DietaRy 
couNseliNg seRvices? estimatiNg iNDiviDualizeD tReatmeNt 
allocatioNs that oPtimize cost-effectiveNess iN Real-WoRlD Data
Signorovitch J.1, Betts K.A.1, Meng X.1, Zhuo Y.2, Wu E.Q.1, Shi L.3
1Analysis Group, Inc., Boston, MA, USA, 2MIT, Cambridge, MA, USA, 3Tulane University, New 
Orleans, LA, USA
Objectives: All people with type 2 diabetes should receive dietary advice. Some 
patients may benefit from additional dietary counseling. This study used recently 
developed statistical methods to estimate the efficiency frontier for individualized 
allocation of dietary counseling services. I. e., for each level of total health care 
expenditure, we estimate the individualized allocation of services that maximizes 
clinical benefit in the population. MethOds: People newly diagnosed with type 2 
diabetes were identified retrospectively from electronic health records and classified 
as receiving vs. not receiving dietary counseling. An individualized effectiveness 
score for achievement of HbA1c < 7% with vs. without counseling was estimated 
using multivariable logistic regression. Demographics, vitals, comorbidities and 
lab values served as candidate predictors. Prediction models were validated in a 
held-out sample. The efficiency frontier was estimated as the convex hull of the 
set of HbA1c control rates and total costs achievable by allocation of dietary coun-
seling based on the effectiveness score. Results: Among 11,819 patients newly 
diagnosed with type 2 diabetes, 22% received dietary counseling and 74% achieved 
HbA1c control. Greater HbA1c, body mass index and age at the time of diagnosis 
were associated with greater effectiveness of dietary counseling. Allocation of all 
newly diagnosed diabetics to dietary counseling was estimated to increase the 
rate of HbA1c control to 80% at a cost of 56 USD per patient vs. current practice. An 
efficient allocation rule (counseling only the 55% of patients predicted to benefit 
most) achieved the same 80% control rate with an incremental cost of 6 USD per 
patient. cOnclusiOns: Retrospective analysis of real-world data identified oppor-
tunities to improve diabetes outcomes vs. current practice with minimal expense 
through individualized allocation of dietary counseling. This result warrants valida-
tion in separate data. The analytical methods warrant broader use to investigate 
efficient allocation of treatments.
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chRoNic caRe maNagemeNt
Gajdos O., Jurickova I.
Czech Technical University in Prague, Kladno, Czech Republic
Objectives: Chronic illness is a prolonging health defect, which is causing a big 
use of financial means for its medical care. These means are not being coordinated 
and used effectively. The aim of this study was to suggest a management care 
system of the chronically ill in the Czech Republic, which should increase the 
quality of medical care and decrease the costs of it. MethOds: There was chosen 
an appropriate diagnosis and concept for the management care, which were based 
on analysis of the current state. The type 2 diabetes mellitus was chosen as an 
appropriate chronic illness and for the management care concept was chosen 
Patient-Centered Medical Home.. The randomized selection of 100 patients was 
made in ordinary diabetes ambulance. The cost of illness was counted from the 
direct costs from the perspective of the society, of the payer and of the patient. 
The cost effectiveness analysis, which was comparing a standard treatment and 
chosen concept, was based on randomized selection, studies of Patient-Centered 
Medical Home and recommended standards of professional society. There were 
also used methods of value engineering especially Saaty matrix and multi-cri-
teria decision making, mainly TOPSIS method for setting the scales of criteria 
and effect. Results: The average costs of one patient are from the perspective 
of the society 29 531 CZK, the payer 20 976 CZK and of the patient 9 196 CZK. The 
Patient–Centered Medical Home has taken the first place in comparison with a 
standard treatment, which was based on the cost of effectiveness analysis. The 
payer will obtain a 25.7x10-5 of the effect for Patient-Centered Medical Home 
according a spent monetary unit. cOnclusiOns: The costs of the chosen concept 
can be more effective. The concept would provide greater prevention, quality and 
coordinated care and can be used for other chronic diseases.
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a comPaRative aNalysis oN the ReimBuRsemeNt status of seNsoR 
augmeNteD PumP theRaPy iN tuRkey aND otheR selecteD couNtRies
Seyhun O., Erdol S., Can H., Erdogan E.
Medtronic, Inc., Istanbul, Turkey
Objectives: Sensor augmented therapy (SAP) with automated insulin suspen-
sion is the most advanced technology for the treatment of severe and moderate 
hypoglisemia in patients with type 1 diabetes mellitus. In order to sustain a bet-
ter uptake of sensor augmented therapy for patients, it is crucial for this tech-
nology to be included in the reimbursement scheme of Turkey and in the other 
countries. Thus, we aimed to study and analyze reimbursement status of this 
technology in Turkey and across other selected countries of Western Asia, North 
America and Western Pacific. MethOds: Mainly official web resources such as 
health authority web pages, direct contact with authority responsibles and pub-
lished articles on SAP are utilized. Results: Most of the countries examined 
have either reimbursement or limited status of SAP. European countries such 
as Ireland, The Netherlands, Sweden, Estonia, Czech Republic; Israel in Western 
Asia, Japan in Western Pacific and USA are the ones where this technology is reim-
bursed mainly for patients with Type 1 Diabetes. Within these selected countries, 
Turkey has a position of having reasonably well defined reimbursement status 
for SAP despite insufficient number of sensors reimbursed - 2 sensors instead 
of 5 sensors a month; which potentially causes an incomplete therapy for the 
patients. cOnclusiOns: Despite the operational hurdles and insufficient number 
of sensors reimbursed per patient in Turkey, the country still stands as a success-
ful example of reimbursement practice, by making this technology available for 
the indicated patients.
1The Johns Hopkins Hospital, Baltimore, MD, USA, 2The Johns Hopkins Medical Institutions, 
Baltimore, MD, USA
Objectives: A pharmacy-based inpatient diabetes management program was 
evaluated to determine if improved glycemic control could be achieved in a gen-
eral medicine patient population. MethOds: A retrospective chart review of 151 
patients with blood glucose (BG) values outside the range 70-180 mg/dL was con-
ducted. Observations for the baseline group (n= 84) were derived from July 2010 and 
for the intervention group (n= 67) in October 2010. The odds of poor glycemic control 
for patients in the intervention versus baseline groups were assessed by multi-
variate generalized estimating equations. These methods were also used to assess 
patient characteristics associated with poor glycemic control. Results: Across all 
patients, no evidence was observed indicating the pharmacy program decreased the 
proportion of days spent out of the targeted blood glucose range [70-180 mg/dL: OR 
0.91 (95% CI: 0.83 – 1.02); 70-250 mg/dL: OR 1.03 (95% CI: 0.88 – 1.24)]. However, the 
subgroup of patients whose admission blood glucose was less than 200 mg/dL (55% 
of intervention group) experienced a significant reduction in days out of range for 
both ranges [70-180 mg/dL (OR: 0.72, 95% CI: 0.61– 0.88) and 70-250 mg/dL (OR: 0.5, 
95% CI: 0.33 – 0.71)]. No improvement in glycemic control was observed in patients 
with an admission BG 200 mg/dL or greater. These patients had more disease- and 
social-related factors associated with poor glycemic control. cOnclusiOns: A sub-
population, patients whose admission glucose was less than 200 mg/dL, experienced 
improvement in glycemic control in the pharmacy-based program. The remaining 
patients were generally more complicated from a disease-state and social perspec-
tive and experienced no improvement. These patients may require a more intense, 
multi-disciplinary approach that is better matched to the constellation of factors 
responsible for their condition.
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comPliaNce to hemogloBiN a1c testiNg RecommeNDatioNs folloWiNg 
iNitial DiaBetes DiagNosis
Palmer L.A.1, Hansen L.G.2
1Truven Health Analytics, Bethesda, MD, USA, 2Truven Health Analytics, Northwood, NH, USA
Objectives: The hemoglobin A1c test (HbA1c) is the favored measure of gly-
cemic control for patients with diabetes. Compliance to recommended testing 
continues to be a challenge. The current analysis evaluates how compliance to 
HbA1c testing varies based on initial HbA1c results. MethOds: Newly diagnosed 
patients with Type II diabetes were identified using the Truven Health MarketScan 
Lab Database (1/1/2010-10/31/2013). Continuous eligibility for the 6 months prior 
and 12 months following diagnosis were required for study inclusion. Patient 
cohorts were created based on first HbA1c test value (< 7.0% [controlled], ≥ 7.0% 
[uncontrolled]). Presence of a subsequent HbA1c test, including test result and 
time to test, were evaluated for these cohorts. Results: A total of 133,011 
patients met the study inclusion criteria; approximately 40% had evidence of 
an initial HbA1c test (n= 33,616 with HbA1c < 7.0%; n= 19,033 with HbA1c ≥ 7.0%). 
Approximately 64% (n= 21,497) of controlled patients had a subsequent HbA1c 
test (86% with HbA1c < 7.0%, 14% with HbA1c ≥ 7.0%); 91% (n= 17,344) of uncon-
trolled patients had a subsequent HbA1c test (36% with HbA1c < 7.0%, 64% with 
HbA1c ≥ 7.0%). Mean times (in days [d]) to subsequent HbA1c test (and result) 
were as follows: Among initially controlled patients: 231d (controlled) and 370d 
(uncontrolled); among initially uncontrolled patients: 238d (controlled) and 212d 
(uncontrolled). Mean time to HbA1c test was significantly longer for controlled 
patients with HbA1c ≥ 7.0% for subsequent test relative to controlled patients 
with HbA1c < 7.0% and to uncontrolled patients with HbA1c ≥ 7.0% for subsequent 
tests. cOnclusiOns: Compliance to recommended timing for HbA1c testing 
is suboptimal in the majority of patients regardless of initial glycemic control. 
Importance of regular HbA1c evaluation should continue to be part of patient 
education – particular for patients who may initial appear to have favorable gly-
cemic control.
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cost-effectiveNess of theiNtRoDuctioN of a NatioNal aDheReNce 
PRogRam foR tyPe 2 DiaBetes iN huNgaRy
Zsólyom A.1, Nagy B.1, Nagyjánosi L.2, Dessewffy Z.3, Steiner T.4, Kaló Z.5, Vokó Z.1
1Eötvös Loránd University, Budapest, Hungary, 2University of Debrecen, Debrecen, Hungary, 
3Novartis Hungary, Budapest, Hungary, 4St. John’s Hospital and North-Buda United Institutions, 
Budapest, Hungary, 5Eötvös Loránd University (ELTE), Budapest, Hungary
Objectives: The Syreon health economic model was developed to predict long 
term effects of screening, treatment and control of type 2 diabetes, by taking into 
account baseline patient characteristics, history of complications, changes in physi-
ological parameters, diabetes treatment and management strategies and screening 
programs. The aim of this analysis was to assess the cost-effectiveness of intro-
ducing a national public health program in Hungary to improve diabetes patient’s 
adherence in comparison to not introducing the program. MethOds: According 
to the guideline of the Hungarian National Diabetes Association, the target HbA1c 
level is below 7%, except for special cases, where it is 8% or less. Without an organ-
ized patient education program 45% of the patients with known diabetes have 
higher than the target HbA1c level. In the studied scenario, the education program 
improves the patient adherence by 30% and increases the proportion of diabetic 
patients achieving the target HbA1c level to 72%. Patients reaching the target HbA1c 
level fully enjoy the benefits of efficient treatment. Non-adherent patients have 
higher HbA1c levels and face higher risk for diabetes-related complications, e. g. 
stroke, neuropathy or retinopathy. Results: The Syreon diabetes model is capable 
of analyzing the consequences of introducing the adherence program for patients 
with diagnosed diabetes. The results of the cost-effectiveness analysis were sensi-
tive to the starting age of the target population and the effectiveness of the training 
program. cOnclusiOns: Organized patient education program was predicted to 
be cost-effective compared with no program in Hungary. The education program 
contributes to better patient adherence resulting in better health and less disease 
related complications.
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other groups, namely sulfonylureas and thiazolidinediones, it has been declining 
each year on average by 2 % and 15 %, respectively. cOnclusiOns: The uptake of 
incretin-based drugs since 2008 has been rapid and their utilization keeps rising, 
apparently at the expense of other drugs, namely older sulfonylurea derivatives and 
thiazolidinediones. Consequently the overall public expenditure on anti-diabetic 
therapy has been increasing.
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NoN-aDheReNce aND NoN-PeRsisteNce RelateD to glP-1 theRaPy 
iN PatieNts With DiaBetes mellitus tyPe 2 (t2Dm): aNalysis of a 
laRge geRmaN claims-BaseD Dataset aND comPaRisoN to oRal aNti-
DiaBetics
Wilke T.1, Groth A.1, Berg B.1, Sikirica M.2, Martin A.A.3, Fuchs A.4, Maywald U.5
1IPAM - Institute for Pharmacoeconomics and Medication Logistics, Wismar, Germany, 
2GlaxoSmithKline, King of Prussia, PA, USA, 3GlaxoSmithKline, Uxbridge, UK, 4AOK Plus, Dresden, 
Germany, 5AOK Plus - Die Gesundheitskasse für Sachsen und Thüringen, Dresden, Germany
Objectives: This study describes the extent of non-adherence (NA) and non-per-
sistence (NP) with Glucagon-like peptide 1 agonists (GLP-1) and oral anti-diabetic 
(OAD) therapy in T2DM patients in clinical practice in Germany. MethOds: Claims 
data from a German sickness fund (AOK Plus) from 2010-2012 were used to identify 
patients with ≥ 1 diagnosis for T2DM. NA/NP were measured for patients initi-
ating new T2DM medication (no prescription of respective medication in prior 6 
months) over a minimum of 12 months. A 100% adherence to therapy was assumed 
equivalent to the drug-specific DDD (defined daily dosage). NP was defined as a 
medication gap ≥ 90 days. Adherence was calculated via medication possession 
ratios (MPR), NA was defined as MPR< 80%. Descriptive analyses with percentage 
of patients affected by NP and/or NA were conducted. Results: The NP analysis, 
included 2,490/42,891 T2DM patients initiating GLP-1s/OADs. Among GLP-1 patients, 
408/1,727/135 received twice-daily (BID; exenatide)/once-daily (OD; liraglutide)/once-
weekly (OW; exenatide) therapies. Average age for GLP-1/OAD users was 56 (SD 
10.8) /67 (SD 12.6) years. After 12 months, the percentage of patients with NP was 
36.83% (all GLP-1s), 42.65% (BID), 37.64% (OD), 27.41% (OW), and 55.87% (OAD). The 
NA analysis included 2,154/34,128 T2DM patients initiating GLP-1/OAD therapy with 
≥ 1 follow-up prescription. Average age was 56 (SD 10.6) /66 (SD 12.2) years. Average 
MPR was 88.2% (all GLP-1s), 87.8% (BID), 88.2% (OD), 95.0% (OW), and 63.2% (OAD). 
Percentage of patients affected by NA was 21.96% (all GLP-1s), 23.98% (BID), 22.00% 
(OD), 5.74% (OW), and 65.82% (OAD). cOnclusiOns: In this German dataset, overall 
patients with T2DM had low rates of adherence and persistence despite the chronic 
nature of the disease and clinical sequelae. Higher adherence and persistence rates 
were observed with GLP-1s than with OAD medications and also with less frequently 
dosed GLP-1s.
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tyPe 2 DiaBetes tReatmeNt PatteRNs acRoss euRoPe
Heintjes E.1, Overbeek J.A.1, Blin P.2, Hall G.C.3, Lapi F.4, Prieto Alhambra D.5, Bezemer I.D.1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2INSERM CIC 
Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France, 3Grimsdyke House, London, UK, 
4Genomedics SRL, Firenze, Italy, 5IDIAP Jordi Gol, Barcelona, Spain
Objectives: To describe the sequential treatment classes of type 2 diabetes (T2DM) 
patients initiating antidiabetic drug therapy in the Netherlands, UK (UK), Spain, 
Italy and France. To describe treatment scaling (intensification or de-intensification) 
in the overall T2DM population. MethOds: Antidiabetic drug use during a 5-year 
study period (2007-2011/2008-2012) (n= 639,088) was obtained from electronic health 
care databases. A standardized analytic tool performed treatment pattern analyses 
in each database for the overall population and those initiating treatment. Oral 
monotherapy was defined as first line, oral dual therapy as second line, multiple oral 
treatments or oral in combination with an injectable as third line and injectables 
only as fourth line therapy. Results: Newly treated patients represented 33-42% 
of the overall T2DM population. Metformin monotherapy was the most common 
initial therapy (65%-87%). Around 35% (Netherlands, Italy, UK) to 45% (Spain, France) 
switched treatment within the study period. The first switch was most often to met-
formin plus a sulfonylurea (SU) in the Netherlands (47%), UK (45%), Spain (22%), Italy 
(17%), but to DPP4 inhibitors in France (15%). DPP4 inhibitor use increased during 
the study period (France 0% to 27%, UK and Spain < 1% to 9%) but remained limited 
in the Netherlands (4%) and Italy (2%). In the total cohort, first line treatment was 
most prevalent over all the years in all countries (around 50%). Intensification was 
the most common switch. Switching patients mostly stepped up or down one line 
at a time, but larger steps were also observed. Fourth line therapy was uncommon 
in France (1-2%) but accounted for about 10% in the other countries. cOnclusiOns: 
SU remained the most common add-on treatment to metformin in most European 
countries while DPP4 inhibitor use was common in France and increased in other 
countries. Most T2DM patients are treated with oral monotherapy.
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exPloRiNg the DeteRmiNaNts of eNDocRiNologist visits iN fRaNce
Andrade L.F.1, Rapp T.2, Sevilla-Dedieu C.1
1MGEN Foundation for Public Health, Paris, France, 2University of Paris Descartes, Paris, France
Objectives: Recent studies reported that seeing an endocrinologist is associated 
with better compliance with guidelines on diabetes management. This study aims 
at investigating the socioeconomic determinants of endocrinologist visits among a 
French population of diabetics. MethOds: We used claim data collected for 66,508 
affiliates of a French social security provider (MGEN). Patients were aged over 18 
and treated for diabetes (types I and II). We ran logistic regressions to explore which 
factors were associated with the probability of consulting an endocrinologist. We 
controlled for patients’ socioeconomic characteristics (sex, age, income, marital 
status, activity status), type of treatment, medical care and health status. We also 
controlled for macro-level variables, such as the cost for a visit, the distance to the 
office and the medical density. Results: Women, married patients, and those work-
ing are more likely to consult an endocrinologist (p< 0.001). Age has a non-linear 
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PRescRiPtioN of RosiglitazoNe aND PioglitazoNe foloWiNg safety 
WaRNiNgs: a comPaRative aNalysis of tReNDs iN DisPeNsiNg PatteRNs 
iN DeNmaRk aND geRmaNy fRom 2007 to 2013
Hostenkamp G.1, Fischer K.E.2
1Center of Health Economics Research (COHERE), Odense M, Denmark, 2University of Hamburg, 
Hamburg, Germany
Objectives: Investigate how official drug safety warnings for thiazolidinediones 
(TZDs, rosiglitazone and pioglitazone) affected prescription trends for TZDs in 
Denmark and Germany and to compare the prescription patterns to data published 
for Australia, UK and the US. MethOds: Identified the timing and content of all 
drug warnings for TZDs using the FDA’s and EMA’s databases. Using pharmaceutical 
claims data on all diabetes patients in Denmark and a large public health insurance 
fund in Germany, plotted the number of defined daily dosages (DDDs) per month for 
rosiglitazone and pioglitazone normalized per 1000 insurees for both countries from 
January 2007 -December 2013. Results: In Denmark rosiglitazone monotherapy 
prescriptions remained almost constant after publication of the safety warnings 
in May 2007 until drug suspension in September 2010, but declined fairly fast in 
Germany. Prescription of rosiglitazone combined with metformin declined by 1/3 
compared to their May 2007 levels in both countries. Overall market penetration of 
rosiglitazone prior to the drug warnings was ~1 DDD per day per 1000 insurees in 
Germany and 0.36 in Denmark, and therefore much lower than in Australia where 
rosiglitazone peaked at about 2 DDDs per 1000 insurees. The FDA’s safety warning 
for increased risk of heart failure for all TZDs in August 2007 did not affect pre-
scription growth rates for pioglitazone in Germany or Denmark. However, pioglita-
zone prescriptions declined after the FDA’s and EMA’s safety warning for possibly 
increased risk of bladder cancer for pioglitazone patients in June and July 2011 in 
both countries. cOnclusiOns: TZD prescriptions in Germany and Denmark did not 
decline as radically after the publication of safety warnings as in other countries. 
Differences in reaction speed may reflect different levels of market penetration prior 
to the drug safety warnings and differences in the intensity of the safety warning 
issued by the drug administration authority.
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assessiNg the meDicatioN use amoNg DiaBetic PatieNts With 
comoRBiD Diseases
Azmi S.1, Mustapha F.I.2, Abdul Aziz S.H.1
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Disease Control Division, Putrajaya, 
Malaysia
Objectives: Type 2 Diabetes is on the rise in many Asian countries with growing 
economic prosperity. Treatment patterns of diabetic patients in South East Asia have 
rarely been studied using administrative data. Our objective was to understand med-
ication use patterns among Malaysian patients with diabetes with comorbidities in 
the primary health care setting. This may be useful for understanding treatment 
strategies in subgroups of patients with diabetes who tend to pose more complex 
challenges in clinical decision-making. MethOds: Data was obtained from diabetic 
patients who were audited in the NDR in 2012. Descriptive analysis was used to 
describe medication usage for patients with various comorbidities. Medications of 
interest were antiplatelet medications, lipid-lowering agents, anti-hypertensive and 
various classes of anti-diabetic medications including insulin. Results: A total of 
130,270 patients were identified with comorbidities. Mean age of patients was 59.8 
years old and 60.2% were female. A majority of patients were hypertensive (70.3%), 
more than half were dyslipidemic (55.1%). Other comorbidities such as retinopathy, 
ischemic heart disease (IHD), cerebrovascular disease, nephropathy, diabetic foot 
ulcer, amputation, hypertension and dyslipidemia were recorded among less than 
10% of patients. Among non-diabetes medications, statins was the most commonly 
used ranging from 64.6% to 86.3% for various comorbidities. This was followed by 
ACE-inhibitors and aspirin. Among anti-diabetic medications, metformin was the 
most commonly prescribed followed by sulfonylureas and insulins. cOnclusiOns: 
The registry data was able to shed light on patterns of medication usage among 
diabetic patients with comorbidities. Perhaps in the future, this data can be used 
to evaluate long-term outcomes among patients on various treatment plans and 
finally to inform more evidence-based clinical management strategies relating to 
medication use.
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six yeaRs of iNcRetiN-BaseD ageNts iN DiaBetes 2ND tyPe tReatmeNt 
iN the czech RePuBlic: the utilizatioN aND exPeNDituRe
Fuksa L.1, Vytrisalova M.2
1General Health Insurance Company of the Czech Republic, Praha, Czech Republic, 2Charles 
University, Faculty of Pharmacy, Hradec Kralove, Czech Republic
Objectives: The objective was to analyze evolving consumption, public costs as 
well as prescription practice pattern of the newer anti-diabetic drugs interfering 
with incretin system, i. e. DPP-IV inhibitors (“gliptins”) and GLP-1 mimetics, and 
compare it to other drugs in the anti-diabetic portfolio. MethOds: The phar-
macy claims-based database of the General Health Insurance Company of the 
Czech Republic (VZP CR) was used as the data source. An insured person with a 
recorded prescription for any of the drugs of interest (ATC3 classification A10B: 
blood glucose-lowering drugs excl. insulins) between 2008 and 2013 was defined as 
a patient. Information on pricing and reimbursement were obtained from the files 
of administrative proceedings at the State Institute for Drug Control. Results: 
Since the introduction of sitagliptin in autumn 2008 its utilization rose to 2.1 DDD/
TID in 2013, which makes it the most prescribed incretin-based drug. Overall con-
sumption of all incretin-based therapies was 5.4 DDD/TID in 2013 and the patient 
number represents 9 % of all patients taking any anti-diabetic drug of the ATC A10B 
group (except for insulins). However, in terms of public costs incretin-based agents 
represent already 55% of all the blood glucose-lowering therapy of the evaluated 
A10B group (insulines excluded). In comparison, the utilization of the 1st line drug 
metformin between 2008 and 2013 has been annually rising by 5 % to 10 %, while in 
